REBIRTH Mitglieder

Stripecke, Renata

Stripecke, Renata, Prof. Dr. rer. nat.

Arbeitsgruppenleiter

REBRITH Unit Regenerative Immune Therapies

Hannover Medical School
Carl-Neuberg-Str. 1
30625 Hannover

Stripecke.Renata(at)mh-hannover.de

Biography / About

Date of Birth:May, 1965
Function:W2 Associate Professor (Tenured), Laboratory Head Regenerative Immune Therapies Applied

Education:

1983 - 1986Bacchaurelate, Biological Sciences, UNICAMP, Sao Paulo, Brazil
1986 - 1988Master’s Degreee, Genetics, UNICAMP, Sao Paulo, Brazil
1988 - 1989Fellow Konrad Adenauer Stiftung, Ludwig Maximilians Univ., Munich
1990 - 1993Dr. rer.nat , Gene Expression, Heidelberg Univ./EMBL, Heidelberg
2000 - 2002Post-doctoral lecturing qualification (Habilitation), Genetics Molecular Biology, Hamburg Univ., Hamburg

Academic appointments and Research posts:

1994 - 1996Post-Doc, HHMI, University of California Los Angeles, USA
1996 - 1999Research Associate, Children’s Hospital Los Angeles, USA
2000 - 2003Assistant Professor of Research, University of Southern California, USA
2003 - 2007Assistant Professor, University of California Los Angeles, USA
Since 2007Group Leader, Rebirth, Hannover Medical School(MHH)

Other professional activities:

2000 - 2001Director of Cell Engineering, Intragene Sciences, Inc.
2003 - 2007Co-Director, UCLA Vector Core, USA
2015Sabbatical, Immunetherapy, Baylor College of Medicine (DFG fellow)

Awards and Prizes:

1994 - 1995DFG Post-doctoral Scholarship (RNA Editing) UCLA/ HHMI
1999 - 2002Leukemia and Lymphoma Society Special Fellow Award (USA)
2000 - 2003National Cancer Institute/NIH K01/ Howard Temin Award (USA)
2001 - 2002DFG Habilitation Scholarship (Gene Therapy), Hamburg University
2002 - 2005Stop Cancer/ USC and UCLA Career Development Award (USA)
2015DFG Sabbatical (Immunotherapy), Baylor College of Medicine

Major research interests:

  • Gene Therapy
  • Immune therapy
  • Hematology
  • Oncology
  • Stem-cell transplantation

Furthermore:

Memberships: ASH (1997), ASGCT (2001), DG-GT (2000), ESCGT (2007).
Reviewer for Fuding Agencies: DFG, DKH, DAAD, Bayimmunet, FWO, Landsteiner.
Reviewer for Journals: Blood, Leukemia, Molecular Therapy, Hum.Gene Therapy, Vaccine.
Scientific Board: Human Gene Therapy, ASGCT (USA), Concern Foundation (USA).

Selected Publications:

  1. Volk V, Schneider A, Spineli LM, Grosshennig A, Stripecke R. The gender gap: discrepant human T-cell reconstitution after cord blood stem cell transplantation in humanized female and male mice. Bone Marrow Transplant. 2016;51(4):596-7.
  2. Daenthanasanmak A, Salguero G, Sundarasetty BS, Waskow C, Cosgun KN, Guzman CA, Riese P, Gerasch L, Schneider A, Ingendoh A, Messerle M, Gabaev I, Woelk B, Ruggiero E, Schmidt M, von Kalle C, Figueiredo C, Eiz-Vesper B, von Kaisenberg C, Ganser A, Stripecke R. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. Mol Ther Methods Clin Dev. 2015;1:14060.
  3. Sundarasetty BS, Chan L, Darling D, Giunti G, Farzaneh F, Schenck F, Naundorf S, Kuehlcke K, Ruggiero E, Schmidt M, von Kalle C, Rothe M, Hoon DS, Gerasch L, Figueiredo C, Koehl U, Blasczyk R, Gutzmer R, Stripecke R. Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. Gene Ther. 2015;22(9):707-20.
  4. Salguero G, Daenthanasanmak A, Munz C, Raykova A, Guzman CA, Riese P, Figueiredo C, Langer F, Schneider A, Macke L, Sundarasetty BS, Witte T, Ganser A, Stripecke R. Dendritic cell-mediated immune humanization of mice: implications for allogeneic and xenogeneic stem cell transplantation. J Immunol. 2014;192(10):4636-47.
  5. Rickmann M, Macke L, Sundarasetty BS, Stamer K, Figueiredo C, Blasczyk R, Heuser M, Krauter J, Ganser A, Stripecke R. Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Ann Hematol. 2013;92(8):1079-90.
  6. Sundarasetty BS, Singh VK, Salguero G, Geffers R, Rickmann M, Macke L, Borchers S, Figueiredo C, Schambach A, Gullberg U, Provasi E, Bonini C, Ganser A, Woelfel T, Stripecke R. Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia. Hum Gene Ther. 2013;24(2):220-37.
  7. Daenthanasanmak A, Salguero G, Borchers S, Figueiredo C, Jacobs R, Sundarasetty BS, Schneider A, Schambach A, Eiz-Vesper B, Blasczyk R, Weissinger EM, Ganser A, Stripecke R. Integrase-defective lentiviral vectors encoding cytokines induce differentiation of human dendritic cells and stimulate multivalent immune responses in vitro and in vivo. Vaccine. 2012;30(34):5118-31.
  8. Salguero G, Sundarasetty BS, Borchers S, Wedekind D, Eiz-Vesper B, Velaga S, Jirmo AC, Behrens G, Warnecke G, Knofel AK, Blasczyk R, Mischak-Weissinger E, Ganser A, Stripecke R. Preconditioning therapy with lentiviral vector-programmed dendritic cells accelerates the homeostatic expansion of antigen-reactive human T cells in NOD.Rag1-/-.IL-2rgammac-/- mice. Hum Gene Ther. 2011;22(10):1209-24.
  9. Pincha M, Salguero G, Wedekind D, Sundarasetty BS, Lin A, Kasahara N, Brugman MH, Jirmo AC, Modlich U, Gutzmer R, Busche G, Ganser A, Stripecke R. Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells. Gene Ther. 2011;18(8):750-64.
  10. Rickmann M, Krauter J, Stamer K, Heuser M, Salguero G, Mischak-Weissinger E, Ganser A, Stripecke R. Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Ann Hematol. 2011;90(9):1047-58.


[zurück zur Liste]
test
Diese Webseite verwendet Cookies und die Webanalyse-Software Google Analytics. Klicken Sie hier für weitere Informationen zum Datenschutz.
Einverstanden